🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Lot B of Influenza virus vaccine

Found 18 matching trials

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

PHASE3

This Phase 3 study evaluates the safety, immunogenicity and lot-to lot cons...

Status

Completed

Location

Optimal Research, LLC

Start Date

2016-07-11

Trial ID

NCT02839330

Treatments Being Tested

aH5N1c Placebo

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine

PHASE3

Studies have shown that a broader spectrum influenza vaccine may help in re...

Status

Completed

Location

Centro de Pesquisa Clínica Universidade Federal do Ceará - UFC (Site FOR01)

Start Date

2021-05-12

Trial ID

NCT03927131

Treatments Being Tested

QIV-IB TIVV-IB TIVY-IB QIV-IB Lot A QIV-IB Lot B QIV-IB Lot C

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

PHASE3

This study is designed to test the immunogenicity and safety of an investig...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-10-01

Trial ID

NCT01196975

Treatments Being Tested

Quadrivalent seasonal influenza vaccine GSK2282512A FluLavalTM-VB FluLavalTM-YB

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

PHASE3

The purpose of this study was to evaluate a single dose of FluBlok in terms...

Status

Completed

Location

Impact Clinical Trials

Start Date

2007-09-15

Trial ID

NCT00539981

Treatments Being Tested

FluBlok®Placebo

Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old

PHASE3

The purpose of this research is to demonstrate immunologic equivalence of t...

Status

Completed

Location

Centro de Salud Galvan

Start Date

2007-11

Trial ID

NCT00617851

Treatments Being Tested

Lot A of Influenza virus vaccine Lot B of Influenza virus vaccine Lot C of Influenza virus vaccine Comparator influenza virus vaccine All 3 consecutive lots of influenza virus vaccine pooled

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children

PHASE2

The present study is designed to evaluate in children (aged between 3 and 9...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-07-23

Trial ID

NCT00502593

Treatments Being Tested

Pandemic Influenza Vaccine (GSK1562902A)Fluarix™

Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

PHASE3

The purpose of this study is to evaluate the immunologic equivalence of thr...

Status

Completed

Location

Anaheim Clincial Trials

Start Date

2014-09

Trial ID

NCT02256488

Treatments Being Tested

TIVc_LOT A TIVc_LOT B TIVc_LOT C TIVf

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

PHASE3

This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT v...

Status

Completed

Location

GSK Investigational Site

Start Date

2006-02-22

Trial ID

NCT00289783

Treatments Being Tested

GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine ActHIB PedvaxHIB Pediarix Prevnar M-M-R II Varivax

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

PHASE3

The purpose of this study is to assess the safety and tolerability of, and ...

Status

Completed

Location

Allgemeines Krankenhaus Wien, Innere Medizin, Waehringer Guertel 18-20

Start Date

2008-08

Trial ID

NCT00711295

Treatments Being Tested

H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

PHASE2

The purpose of this study is to evaluate the safety, reactogenicity, and im...

Status

Completed

Location

Indago Research & Health Center, Inc.

Start Date

2024-07-15

Trial ID

NCT06508320

Treatments Being Tested

mRNA-1083

Previous Next